Uses of Kalbezar 200mg

Kalbezar 200mg is used in the treatment of non-small cell lung, pancreatic and bladder cancers. The drug is prepared in the form of lyophilized powder and administered intravenously.

Kalbezar medicine 200mg is prepared in the form of lyophilized powder for injection, with each bottle of 200mg Gemcitabine in the form of Gemcitabine HCl 200mg.
With the main use of killing and preventing the growth of cancer cells, Kalbezar 200mg is indicated for the treatment of breast cancer, pancreatic cancer, non-small cell lung cancer, cancer. bladder, ovarian cancer.

The main effect of Kalbezar 200mg to kill and prevent the growth of cancer cells is thanks to the active ingredient Gemcitabine. Gemcitabine is known to be radiosensitive even at concentrations below cytotoxic doses.
Gemcitabine in Kalbezar 200mg has the effect of killing cancer cells through inhibiting its DNA synthesis, thereby preventing cancer cell growth through the G1/S phase boundary. In addition, in lymphocytes, Gemcitabine induces DNA fragmentation, promoting cell destruction (including cancer cells) according to a predetermined schedule.

In some cases of the following cancers, Gemcitabine 200mg is indicated for the treatment of
Non-small cell lung cancer. Pancreatic Cancer . Pancreatic cancer resistant to 5-FU. Bladder cancer. Breast cancer.

Patients who are sensitive to the drug, sensitive to Gemcitabine Patients with bone marrow suppression, if using Kalbezar 200mg but the situation worsens, they should also temporarily stop, reduce the dose or stop it. Patients who are suffering from shingles Patients with impaired liver and kidney function when using Kalbezar must be extremely cautious because there have been cases of blood in urine. Patients who have undergone chemotherapy / radiation therapy.

Dosage of Kalbezar 200mg in patients with non-small cell lung cancer:
Monotherapy: In adults, the recommended dose is 1,000 mg/m2 intravenously over 30 minutes/time. This dose is repeated once a week, maintained for 3 weeks, followed by a 1-week break. Then repeat the dose used in the previous 4 weeks (3 weeks infusion - 1 week break). Consider dose reduction based on the degree of toxicity observed in the patient. Using Kalbezar with other drugs: In adults, Kalbezar 200mg was studied in combination with cisplatin according to the following 2 treatment regimens: 3-week regimen: Using Kalbezar 200mg 1,250 mg/m2, injection or intravenous infusion for 30 days minutes on the 1st and 8th day of a 21-day cycle. For cisplatin the dose would be 75-100 mg/m2 on day 1 of a 21-day cycle, prior to Kalbezar 200 mg. Adjust the dose of both drugs based on the degree of toxicity in each patient. 4-week regimen: Use Kalbezar 200 mg 1,000 mg/m2, intravenous infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. This regimen has a recommended dose of cisplatin 75-100 mg/m2 on day 1 of the cycle, following Kalbezar 200 mg. The dose may be reduced based on the degree of toxicity in the patient. Dosage of Kalbezar 200mg for Pancreatic Cancer:
In adults, the recommended dose for Kalbezar 200mg is 1,000 mg/m2 administered intravenously over 30 minutes. Repeat this dose once a week for a period of 7 weeks. Then stop for 1 week. After the above 8 weeks have passed, continue taking this dose once a week for 3 weeks, then stop for 1 week. Dosage in the last 4 weeks will be repeated, considering dose reduction based on the degree of toxicity observed in the patient. Kalbezar 200mg dose for breast cancer:
Kalbezar 200mg for breast cancer is recommended in combination with a paclitaxel, dose of 1250mg/m2, administered by injection or intravenous infusion over 30 minutes on days 1 and 8 of a 21-day cycle. With Paclitaxel, the dose will be 175mg/m2 and intravenous infusion more than 3 hours after Gemcitabine administration. Dosage of Kalbezar 200mg in combination with Cisplatin in the treatment of bladder cancer. The recommended dose of Kalbezar 200mg is 1,000 mg/m2, administered as a 30-minute intravenous infusion on days 1, 8 and 15 of a 28-day (4-week) cycle. The recommended dose for Cisplatin is 70 mg/m2 intravenously on day 1 after Kalbezar 200 mg or on day 2 of each 28-day (4-week) cycle. The 4-week dosing cycle will be repeated as above. Reduce drug dose according to the degree of toxicity occurs in the patient. The use of high-dose cisplatin should be considered when a clinical trial reported greater myelosuppression with cisplatin at a dose of 100 mg/m2.

As a drug that destroys and prevents the growth of cancer cells, Kalbezar 200mg of course does not avoid causing side effects.
Some unwanted side effects when using Kalbezar are: Myelosuppression, abnormal liver enzymes, nausea. When these symptoms are present, you should immediately notify a specialist to stop the drug or combine treatment.

Subjects are cancer patients, so it is necessary to closely monitor the patient's situation when using Kalbezar 200mg. Kalbezar 200mg should not be used for pregnant or lactating women because it may be toxic to the fetus and child. breastfeeding. Kalbezar 200mg is a drug for intravenous infusion, used in the treatment of a number of cancers today. The drug has many side effects as well as contraindications in some special cases. Patients should be cautious when taking the drug and should notify the doctor immediately when experiencing unwanted effects